Prostate Cancer

Prostate Cancer

Biochemical Relapse Free Survival of Patients With Low-Risk Prostate Cancer by Treatment Typeᵃ (N = 2257)

1996-2018

Number at Risk 5 Years 10 Years 15 Years
External Beam Radiotherapy (N = 505) 96.0% (345) 85.6% (144) 66.5% (26)
Low-Dose-Rate Brachytherapy (N = 1752) 95.2% (839) 85.9% (181) 69.2% (22)

EBRT= External Beam Radiotherapy, LDRBT = Low-Dose-Rate Brachytherapy

ᵃNational Comprehensive Cancer Network (NCCN). Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology. V.2.2007. Fort Washington, PA: NCCN; 2007.

Biochemical Relapse Free Survival of Patients With Intermediate-Risk Prostate Cancer by Treatment Typeᵃ (N = 2288)

1996-2018

Number at Risk 5 Years 10 Years 15 Years
External Beam Radiotherapy (N = 530) 85.9% (295) 73.1% (125) 55.8% (11)
Low-Dose-Rate Brachytherapy (N = 1758) 90.6% (564) 74.2% (68) 62.9% (7)

EBRT= External Beam Radiotherapy, LDRBT = Low-Dose-Rate Brachytherapy

ᵃNational Comprehensive Cancer Network (NCCN). Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology. V.2.2007. Fort Washington, PA: NCCN; 2007.

Biochemical Relapse Free Survival of Patients With High-Intermediateᵃ Risk Prostate Cancer by Treatment Typeᵃ⁻ᵇ (N = 564)

1996-2018

Number at Risk 5 Years 10 Years 15 Years
External Beam Radiotherapy (N = 241) 80.5% (134) 63.3% (55) 41.7% (11)
Low-Dose-Rate Brachytherapy (N =323) 77.3% (86) 48.0% (6) NA

EBRT= External Beam Radiotherapy, LDRBT = Low-Dose-Rate Brachytherapy

ᵃNational Comprehensive Cancer Network (NCCN). Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology. V.2.2007. Fort Washington, PA: NCCN; 2007.

ᵇHigh-Intermediate risk is defined as having ≥ 2 Intermediate risk factors.

Biochemical Relapse Free Survival of Patients With High-Risk Prostate Cancer by Treatment Typeᵃ (N = 963)

1996-2018

Number at Risk 5 Years 10 Years 15 Years
External Beam Radiotherapy (N = 611) 70.8% (280) 46.7% (92) 35.1% (11)
Low-Dose-Rate Brachytherapy (N = 352) 66.9% (90) 43.1% (9) NA

EBRT= External Beam Radiotherapy, LDRBT = Low-Dose-Rate Brachytherapy

ᵃNational Comprehensive Cancer Network (NCCN). Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology. V.2.2007. Fort Washington, PA: NCCN; 2007.

Cumulative Mortality Due to Prostate Cancer of Patients With Low-Risk Prostate Cancer by Treatment Typeᵃ (N= 2257)

1996-2018

Number at Risk 5 Years 10 Years 15 Years
External Beam Radiotherapy (N = 505) 0.9% (396) 1.6% (226) 4.8% (63)
Low-Dose-Rate Brachytherapy (N = 1752) 0.2% (985) 1.7% (284) 2.4% (46)

ᵃNational Comprehensive Cancer Network (NCCN). Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology. V.2.2007. Fort Washington, PA: NCCN; 2007.

Cumulative Mortality Due to Prostate Cancer of Patients With Intermediate-Risk Prostate Cancer by Treatment Typeᵃ (N= 2288)

1996-2018

Number at Risk 5 Years 10 Years 15 Years
External Beam Radiotherapy (N = 530) 1.7% (382) 4.9% (214) 8.1% (32)
Low-Dose-Rate Brachytherapy (N = 1758) 0.3% (690) 2.1% (135) 6.4% (17)

ᵃNational Comprehensive Cancer Network (NCCN). Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology. V.2.2007. Fort Washington, PA: NCCN; 2007.

Cumulative Mortality Due to Prostate Cancer of Patients With High-Intermediate Risk Prostate Cancer by Treatment Typeᵃ⁻ᵇ (N= 564)

1996-2018

Number at Risk 5 Years 10 Years 15 Years
External Beam Radiotherapy (N = 241) 2.4% (184) 4.5% (111) 9.3% (35)
Low-Dose-Rate Brachytherapy (N = 323) 1.7% (128) 1.7% (28) 1.7% (3)

ᵃNational Comprehensive Cancer Network (NCCN). Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology. V.2.2007. Fort Washington, PA: NCCN; 2007.

ᵇHigh-intermediate risk is defined as having ≥ 2 intermediate risk factors.

Cumulative Mortality Due to Prostate Cancer of Patients With High-Risk Prostate Cancer by Treatment Typeᵃ (N= 963)

1996-2018

Number at Risk 5 Years 10 Years 15 Years
External Beam Radiotherapy (N = 611) 5.6% (437) 13.5% (240) 18.9% (53)
Low-Dose-Rate Brachytherapy (N = 352) 4.4% (158) 5.7% (32) 5.7% (5)

ᵃNational Comprehensive Cancer Network (NCCN). Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology. V.2.2007. Fort Washington, PA: NCCN; 2007.